In both children and adults, chronically low calcium intake can undermine the mineralization of teeth and supporting bone, contributing to enamel hypoplasia, root resorption, and loss of alveolar bone that stabilizes the teeth. Epidemiologic studies have linked lower dietary calcium and dairy intake with higher rates of periodontitis, tooth mobility, and tooth loss, especially in older adults and postmenopausal women. The encouraging piece is that maintaining adequate calcium (alongside vitamin D and good oral hygiene) appears to support healthier periodontal bone and may reduce the risk of dental defects and tooth loss over time. This medication is commonly used for Stomach Acid.
Nishida M, Grossi SG, Dunford RG, Ho AW, Trevisan M, Genco RJ. Calcium and the risk for periodontal disease. J Periodontol. 2000 Jul;71(7):1057-66. Nascimento GG, Leite FRM, Gonzalez-Chica DA, Peres KG, Peres MA. Dietary vitamin D and calcium and periodontitis: A population-based study. Front Nutr. 2022 Dec 22;9:1016763. Miley DD, Garcia MN, Hildebolt CF, Shannon WD, Couture RA, Anderson Spearie CL, Dixon DA, Langenwalter EM, Mueller C, Civitelli R. Cross-sectional study of vitamin D and calcium supplementation effects on chronic periodontitis. J Periodontol. 2009 Sep;80(9):1433-9. Nishida, M., Grossi, S.G., Dunford, R.G., Ho, A.W., Trevisan, M. and Genco, R.J. (2000), Calcium and the Risk For Periodontal Disease. Journal of Periodontology, 71: 1057-1066.
Some side effects may be linked to nutrient depletion caused by this medication.
Studies find that proton pump inhibitors (PPIs) may increase your risk of magnesium deficiency. A large study involving over 100,000 participants found a significant association between PPI use and lower magnesium levels (hypomagnesemia). PPIs work by reducing stomach acid production, which can also play a role in magnesium absorption. Individuals taking PPIs, particularly long-term use, should consider magnesium supplementation to help protect against deficiency.
Long-term use of PPIs might raise the risk of calcium deficiency and weaken bones. A potential mechanism for this is chronic hypergastrinemia, a condition where the stomach produces excess gastrin due to PPI use. This can lead to parathyroid hyperplasia, where the parathyroid glands overproduce a hormone that pulls calcium from bones. Additionally, PPIs significantly reduce stomach acid production, which can hinder calcium absorption from food in the intestines. Individuals taking PPIs, especially individuals at higher risk of bone issues or those on long-term PPI therapy, should consider calcium supplementation to help protect against deficiency.
There is evidence that proton pump inhibitors (PPIs) might decrease vitamin C levels in the body. A study showed that even a short course of omeprazole, a common PPI, reduced vitamin C levels in healthy volunteers, regardless of their dietary intake. This suggests that PPIs may reduce the bioavailability of vitamin C, meaning the body has a harder time absorbing and using it. Vitamin C plays a crucial role in immune function and antioxidant defenses and therefore individuals using PPI therapy should consider supplementation with vitamin C to protect against a deficiency.